GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Personal Services » Medifast Inc (NYSE:MED) » Definitions » Gross Profit

Medifast (Medifast) Gross Profit : $656.8 Mil (TTM As of Mar. 2024)


View and export this data going back to 1981. Start your Free Trial

What is Medifast Gross Profit?

Medifast's gross profit for the three months ended in Mar. 2024 was $127.3 Mil. Medifast's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $656.8 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Medifast's gross profit for the three months ended in Mar. 2024 was $127.3 Mil. Medifast's Revenue for the three months ended in Mar. 2024 was $174.7 Mil. Therefore, Medifast's Gross Margin % for the quarter that ended in Mar. 2024 was 72.85%.

Medifast had a gross margin of 72.85% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Medifast was 75.83%. The lowest was 71.34%. And the median was 74.27%.

Warning Sign:

Medifast Inc gross margin has been in long-term decline. The average rate of decline per year is -1.1%.


Medifast Gross Profit Historical Data

The historical data trend for Medifast's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medifast Gross Profit Chart

Medifast Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 536.86 697.82 1,127.60 1,140.41 775.85

Medifast Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 246.39 210.72 177.38 141.37 127.29

Competitive Comparison of Medifast's Gross Profit

For the Personal Services subindustry, Medifast's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medifast's Gross Profit Distribution in the Personal Services Industry

For the Personal Services industry and Consumer Cyclical sector, Medifast's Gross Profit distribution charts can be found below:

* The bar in red indicates where Medifast's Gross Profit falls into.



Medifast Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Medifast's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1072.054 - 296.204
=775.9

Medifast's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=174.739 - 47.447
=127.3

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $656.8 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Medifast's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=127.3 / 174.739
=72.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Medifast  (NYSE:MED) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Medifast had a gross margin of 72.85% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Medifast Gross Profit Related Terms

Thank you for viewing the detailed overview of Medifast's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Medifast (Medifast) Business Description

Traded in Other Exchanges
Address
100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
Executives
Jeffrey J Brown director 19900 MACARTHUR BLVD, SUITE 570, IRVINE CA 92612
Andrea B Thomas director C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Michael A. Hoer director MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Scott Schlackman director 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Hallquist Constance J. director 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Elizabeth A. Geary director C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Daniel R Chard director, officer: Chief Executive Officer NU SKIN ENTERPRISES, INC., 75 WEST CENTER STREET, PROVO UT 84601
Jonathan Barrett Mackenzie officer: VP, Finance & CAO 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Kevin G Byrnes director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Michael C Macdonald director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
James P. Maloney officer: Chief Financial Officer 415 HOLIDAY DRIVE, PITTSBURGH PA 15220
Ming Xian director MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Carl E Sassano director C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Joseph P Kelleman officer: (Interim) CFO 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Timothy G Robinson officer: Chief Financial Officer C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117